| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 11/12/2003 | EP0517850B1 Compositions and methods of treatment of sympathetically maintained pain |
| 11/12/2003 | CN1455681A Contraception process and administration for same |
| 11/12/2003 | CN1455680A MUCl extracellular domain and cancer treatment compositions and methods derived therefrom |
| 11/12/2003 | CN1455673A Antibiotics from bacteria isolated from amphibian skin and biological active extrat derivated from same |
| 11/12/2003 | CN1455667A Use of an epoxy-sterodal aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects |
| 11/12/2003 | CN1454900A Glucose and insulin response element |
| 11/12/2003 | CN1127338C Anti-vaginitis composition for topiical use comprising one or move anti-vaginitis medicaments and one or more local anaesthetics |
| 11/12/2003 | CN1127333C Local pharmaceutical composition comprising cholinergic agent or calcium channel blocker |
| 11/12/2003 | CN1127294C Endoparasiticidal and ectoparasiticidal agents |
| 11/11/2003 | US6646162 Compounds and compositions for delivering active agents |
| 11/11/2003 | US6646157 Method for making HBED |
| 11/11/2003 | US6646006 Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
| 11/11/2003 | US6646004 Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| 11/11/2003 | US6645997 Agonists of peroxisome proliferator activated receptor (PPAR) alpha and/or gamma |
| 11/11/2003 | US6645988 Pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors with fast acting buffer; gastric acid stability for enteral administration |
| 11/11/2003 | US6645972 Administering nucleoside analogues such as beta-L-dioxolane cytidine as tyrosine kinase inhibitors or anticarcinogenic agents |
| 11/11/2003 | US6645970 Preventing T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer |
| 11/11/2003 | US6645966 Reverse malaria drug resistance |
| 11/11/2003 | US6645946 Delivery of a therapeutic agent in a formulation for reduced toxicity |
| 11/11/2003 | US6645775 Insulin-like growth factor agonist molecules |
| 11/11/2003 | US6645753 Polynucleotides; antisense agents; MAP-kinases; nucleotide sequences; use of polypeptides to identify agents modulating signal transduction leading to cell proliferation, differen-tiation, survival and treatment of such conditions (cancer) |
| 11/11/2003 | US6645741 Screening nucleotide sequences samples; obtain nucleotide sequences, incubate with primers, amplify nucleotide sequences, analyzing amplified nucleotide sequences |
| 11/11/2003 | US6645531 Halting, diminishing, or inhibiting the growth of at least one of a bacterium, a fungus; a parasitic microbe, and a virus, which method comprises administering at least one electron active compound |
| 11/11/2003 | US6645521 Local prevention or amelioration of pain from surgically closed wounds |
| 11/11/2003 | US6645513 Treatment of skin with adenosine or adenosine analog |
| 11/11/2003 | US6645510 Method of treating topical ailments |
| 11/11/2003 | US6645506 Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil |
| 11/11/2003 | US6645501 Anti-pathogen system and methods of use thereof |
| 11/11/2003 | US6645482 Sulfated proteoglycan; one or more of a hexosamine sulfate,a flavone, olive kernel extract, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of CRH, caffeine, and a polyamine. |
| 11/11/2003 | US6645468 Medicinal aerosol formulation |
| 11/11/2003 | US6645467 Administering a dose of a mixture of lipid crystals, as an aerosol; propellants are evaporated as aerosolized mixture of lipid crystals come into contact with, and deposits upon the epithelial lining of the upper respiratory system |
| 11/11/2003 | US6645168 Decreasing postoperative analgesic opiate requirement; reducing operating site time for patient |
| 11/11/2003 | US6644320 Treatment of hepatitis C using hyperthermia |
| 11/11/2003 | CA2292497C Dietary compositions for enhancing metabolism and alleviating oxidative stress |
| 11/09/2003 | CA2385774A1 Composition to reduce food cravings and supress the appetite |
| 11/06/2003 | WO2003091456A1 A dna enzyme to inhibit plasminogen activator inhibitor-1 |
| 11/06/2003 | WO2003091414A2 Adipocyte complement related protein zacrp8 |
| 11/06/2003 | WO2003091403A2 Genetic and epigenetic manipulation of abc transporters and ecto-phosphatases |
| 11/06/2003 | WO2003091387A2 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands |
| 11/06/2003 | WO2003091239A1 Estrogen receptor modulators |
| 11/06/2003 | WO2003091232A2 Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them |
| 11/06/2003 | WO2003090870A1 Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency |
| 11/06/2003 | WO2003090785A1 Methods and conpositions for treating, preventing or delaying onset of a neoplasm |
| 11/06/2003 | WO2003090784A1 Treatment of metabolic syndrome |
| 11/06/2003 | WO2003090783A1 Preventive/remedy for diabetes |
| 11/06/2003 | WO2003090778A2 Dna vaccine combined with an inducer of tumor cell apoptosis |
| 11/06/2003 | WO2003090776A1 Compositions and methods for diagnosis and treatment of cardiovascular disorders |
| 11/06/2003 | WO2003090765A1 Medicinal compositions containing phtocrosslinkable chitosan derivative |
| 11/06/2003 | WO2003090758A1 Method for treating inflammatory disorders |
| 11/06/2003 | WO2003090756A1 Anti-acne compositions and methods of use |
| 11/06/2003 | WO2003090753A1 Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention |
| 11/06/2003 | WO2003090743A1 Prevention and treatment of functional somatic disorders, including stress-related disorders |
| 11/06/2003 | WO2003090742A1 Pharmaceutical composition comprising a lipase inhibitor and glucomannan |
| 11/06/2003 | WO2003090740A1 Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori |
| 11/06/2003 | WO2003090737A2 Methods and compositions for treatment of cancer pain |
| 11/06/2003 | WO2003090731A1 Use of gabab receptor positive modulators in gastro-instestinal disorders |
| 11/06/2003 | WO2003090729A1 Transdermal analgesic systems with reduced abuse potential |
| 11/06/2003 | WO2003090723A1 Modified-release vasopeptidase inhibitor formulation, combinations and method |
| 11/06/2003 | WO2003090705A1 Biologically active compounds for the modification of bodily odours |
| 11/06/2003 | WO2003090699A1 Cosmetic composition for promoting hair growth and/or preventing or delaying hair loss |
| 11/06/2003 | WO2003090687A2 Using heat shock proteins to increase immune response |
| 11/06/2003 | WO2003090686A2 Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
| 11/06/2003 | WO2003090682A2 Treatment and prevention of pulmonary conditions |
| 11/06/2003 | WO2003090681A2 SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-κB INHIBITORS AND ANTI-NEOPLASTIC AGENTS |
| 11/06/2003 | WO2003090676A2 Immunogenic agent therapy using plasmapheresis or exchange transfusion |
| 11/06/2003 | WO2003090673A2 Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals |
| 11/06/2003 | WO2003090671A2 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance |
| 11/06/2003 | WO2003090599A2 Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head |
| 11/06/2003 | WO2003090547A1 A composition comprising waxy acids for effecting serum cholesterol levels |
| 11/06/2003 | WO2003090512A2 Regeneration of endogenous myocardial tissue by induction of neovascularization |
| 11/06/2003 | WO2003080112A3 Imidazoquinolineamines as adjuvants in hiv dna vaccination |
| 11/06/2003 | WO2003079981A3 Bioadhesive drug delivery system |
| 11/06/2003 | WO2003075685A3 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof |
| 11/06/2003 | WO2003068153A3 CARDIAC-SPECIFIC 11β HYDROXYSTEROID DEHYDROGENASE TYPE 2 TRANSGENIC MICE |
| 11/06/2003 | WO2003066889A3 Assay for acytyltransferase or deacetylase activity |
| 11/06/2003 | WO2003057166A3 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 11/06/2003 | WO2003046570A3 Glycoprotein and apolipoprotein biopolymer markers predictive of alzheimers disease |
| 11/06/2003 | WO2003039455A3 Methods of treating endometreosis |
| 11/06/2003 | WO2003032985A3 Concomitant oral and topical administration of anti - infective agents |
| 11/06/2003 | WO2003031939A3 Protein modification and maintenance molecules |
| 11/06/2003 | WO2003030934A3 Cpg formulations and related methods |
| 11/06/2003 | WO2003030908A3 Inhibitors of the egf receptor for the treatment of thyroid cancer |
| 11/06/2003 | WO2003027263A3 Proteins associated with cell growth, differentiation, and death |
| 11/06/2003 | WO2003026589A3 Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
| 11/06/2003 | WO2003013549A3 Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals |
| 11/06/2003 | WO2003007686A3 Use of copper chelators to inhibit the inactivation of protein c |
| 11/06/2003 | WO2003002135A3 Herbal composition |
| 11/06/2003 | WO2003000177A3 Stable controlled release pharmaceutical compositions containing pravastatin |
| 11/06/2003 | WO2002098916A3 Transcriptional regulator of genes involved in the control of cell growth or cell proliferation. use of said regulator as a therapeutic or diagnostic agent |
| 11/06/2003 | WO2002076979A8 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists |
| 11/06/2003 | WO2002076482B1 USE OF IKK-β INHIBITORS AND METHOD FOR DISCOVERY OF SAID INHIBITORS |
| 11/06/2003 | WO2002072631A3 Mhc molecule constructs and their usesfor diagnosis and therapy |
| 11/06/2003 | WO2002070657A8 93870, a human g-protein coupled receptor and uses therefor |
| 11/06/2003 | WO2002070509A8 Antagonists of mcp-1 function and methods of use thereof |
| 11/06/2003 | WO2002069950A3 Tumor treatement with a combination of a substrate of mrp5 and modulators of mrp5 |
| 11/06/2003 | WO2002060900A8 Antagonists of mcp-1 function and methods of use thereof |
| 11/06/2003 | WO2002060491A3 Stabilization of radiopharmaceutical compositions using a hydrophilic thioether or a hydrophilic 6-hydroxy chroman |
| 11/06/2003 | WO2002059558A8 Means and methods for treatment evaluation |
| 11/06/2003 | WO2002059312A3 Cell adhesion proteins |
| 11/06/2003 | WO2002059117A8 Piperazine- and piperidine-derivatives as melanocortin receptor agonists |